Parnax Lab Limited (BOM:506128)
134.05
-1.55 (-1.14%)
At close: Jun 18, 2026
Parnax Lab Revenue
In the fiscal year ending March 31, 2026, Parnax Lab had annual revenue of 2.49B INR with 32.36% growth. Parnax Lab had revenue of 696.25M in the quarter ending March 31, 2026, with 41.86% growth.
Revenue
2.49B
Revenue Growth
+32.36%
P/S Ratio
0.62
Revenue / Employee
207.12M
Employees
12
Market Cap
1.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.49B | 607.65M | 32.36% |
| Mar 31, 2025 | 1.88B | -10.25M | -0.54% |
| Mar 31, 2024 | 1.89B | 211.98M | 12.65% |
| Mar 31, 2023 | 1.68B | 45.75M | 2.81% |
| Mar 31, 2022 | 1.63B | 729.06M | 80.89% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bilcare | 7.34B |
| Bal Pharma | 3.12B |
| Lactose (India) | 1.63B |
| Aayush Wellness | 1.55B |
| Oxygenta Pharmaceutical | 1.13B |
| Accretion Pharmaceuticals | 898.18M |
| Coral Laboratories | 859.00M |
| Concord Drugs | 787.37M |